Thrombolysis

Related by string. thrombolysis * * directed thrombolysis . intravenous thrombolysis *

Related by context. All words. (Click for frequent words.) 77 Percutaneous Coronary Intervention 76 Myocardial Infarction TIMI 76 Acute Myocardial Infarction 75 Myocardial Infarction Study 73 Myocardial Infarction 73 Acute Ischemic Stroke 72 Infarction 72 TIMI 72 Left Ventricular 71 Carotid 71 Randomized Evaluation 71 Acute Coronary Syndromes 71 Angiographic 71 Coronary Artery Bypass Graft 70 Patients Undergoing 70 Carotid Revascularization Endarterectomy vs. 70 RE LY ® 70 periprocedural 70 Risk Stratification 70 Stenting 70 Prospective Randomized 70 alteplase 69 Ischemic Stroke 69 primary percutaneous coronary 69 thrombolytic therapy 69 carotid artery stenting CAS 69 Ischemic 69 STRIDE PD 69 SYNTAX 69 unfractionated heparin UFH 69 Acute Decompensated Heart Failure 69 patients undergoing percutaneous 69 Patient Outcomes 68 Intracranial 68 Infarct 68 Clinical Outcome 68 Events MACE 68 XIENCE V PROMUS Stent 68 coronary intervention 68 Unstable Angina 68 Patency 68 Cardiac Resynchronization Therapy 68 Venous Thromboembolism 68 Randomized Clinical Trial 68 Myocardial Infarction TIMI Study 67 NSTE ACS 67 Carotid Endarterectomy 67 Multicenter 67 Pivotal Trial 67 Oral Fingolimod 67 Acute Myocardial 67 Abciximab 67 thrombus aspiration 67 RE LY 67 Endarterectomy 67 coronary revascularization 67 Ranolazine 67 liver resection 67 tenecteplase 67 carotid endarterectomy CEA 67 Acute Coronary Syndrome 67 Coronary Artery 67 ST Segment Elevation 67 Restenosis 67 Peripheral Arterial 67 Carotid Stenting 67 Primary endpoints 67 ECASS 67 NYHA functional class 67 Myocardial Ischemia 67 Metastatic Renal Cell Carcinoma 67 Unfractionated Heparin 67 thrombolysis 66 transthoracic 66 Left Ventricular Dysfunction 66 angioplasty stenting 66 rFVIIa 66 sirolimus eluting stents 66 Cardiovascular Events 66 Solid Tumors 66 FDG-PET/CT 66 Stenting Trial CREST 66 Nesiritide 66 rt PA 66 Intracranial Aneurysms 66 Index CDAI 66 multicentre randomized 66 tirofiban 66 carotid artery stenosis 66 Coronary Artery Bypass Surgery 66 EURIDIS 66 Percutaneous Coronary Interventions 66 unstable angina UA 66 EVEREST II 66 multicenter randomized controlled 66 Ventricular Tachycardia 66 Chronic Heart Failure 66 RECIST Response Evaluation Criteria 66 Resection 66 Heart Failure Patients 66 Afib 66 Guideline Update 66 Renal Artery 66 RENAL 66 ipsilateral stroke 66 Radiofrequency Ablation 66 Severe Sepsis 66 ST Elevation Myocardial 66 stage IIIB 66 prospective multicenter 66 reinfarction 66 Echocardiographic 66 Brief Psychiatric 66 Val HeFT 66 bypass graft CABG surgery 66 post thrombotic syndrome 66 composite endpoint 66 ARIXTRA 66 echocardiographic 65 Reperfusion 65 Coronary Angiography 65 bronchial hyperresponsiveness 65 Subgroup Analysis 65 Kaplan Meier analysis 65 intra arterial 65 MACCE 65 Phase 2b Study 65 Cholesterol Levels SPARCL 65 fibrinolytic therapy 65 NATRECOR ® 65 Acute Coronary Syndromes ACS 65 Treatment Outcome 65 Ejection Fraction 65 reperfusion therapy 65 acute coronary syndromes ACS 65 Patients Treated 65 Aneurysm Repair 65 Ventricular 65 left ventricular dysfunction 65 CT Angiography 65 Enoxaparin 65 tolvaptan 65 Randomized Controlled Trials 65 coronary stenosis 65 Cardiac Resynchronization 65 glycoprotein IIb IIIa inhibitors 65 Stent Thrombosis 65 undergoing coronary artery 65 MR Angiography 65 Fondaparinux 65 Aortic Valve Replacement 65 Stent Restenosis 65 ischemic cardiomyopathy 65 nonrandomized 65 Renal Function 65 Acute Stroke 65 Carotid Artery 65 Liver Metastases 65 carotid stenosis 65 Aortic Dissection 65 Anticoagulation 65 Castration Resistant Prostate Cancer 65 cilostazol 65 Edge STudy 65 symptomatic VTE 65 ATACAND 65 occlusive disease 65 saphenous vein graft 65 Aortic Stenosis 65 Hospitalized Patients 65 transurethral resection 64 Platelet Inhibition 64 recurrent DVT 64 Clinical Trial Evaluating 64 Recurrent Stroke 64 NAVISTAR R 64 Catheter Ablation 64 Cardiovascular Outcomes 64 TRITON TIMI 64 postoperative AF 64 Ischaemic 64 Adjuvant Therapy 64 Metastatic Prostate Cancer 64 HSCT 64 carotid artery stenting 64 Drug Eluting Stents 64 Septic Shock 64 prospective multicenter study 64 ACTEMRA TM 64 Randomized Study 64 thromboembolic events 64 β blockers 64 coronary artery stenosis 64 prospective multicenter randomized 64 NATRECOR R 64 Pegylated Liposomal Doxorubicin 64 ENGAGE AF TIMI 64 Aortic Valve 64 unstable angina pectoris 64 aspartate aminotransferase AST 64 Fracture Risk 64 COPERNICUS 64 Autologous Stem Cell Transplantation 64 Critical Limb Ischemia CLI 64 Psoriasis Area 64 undergoing Percutaneous Coronary 64 substudy 64 invasive aspergillosis 64 duplex ultrasonography 64 OPCAB 64 thromboprophylaxis 64 Revascularization 64 CHAMPION PCI 64 Aggressive Reduction 64 Myocardial 64 Randomised 64 artery stenosis 64 BENICAR HCT 64 NMIBC 64 mcg QD 64 Pooled Analysis 64 Elderly Patients 64 percutaneous coronary interventions 64 acute myocardial infarction AMI 64 percutaneous transluminal coronary angioplasty 64 pericardial effusion 64 transcranial Doppler ultrasound 64 MADIT II 64 ExTRACT TIMI 64 Hypotension 64 Relapsing Multiple Sclerosis 64 Lung Injury 64 Overactive Bladder 64 Monotherapy 64 Coronary artery bypass grafting 64 Aggressive Drug Evaluation 64 Natalizumab 64 Bivalirudin 64 Patients Treated With 64 CARE HF 64 Intravascular 64 thromboembolic 64 chemoradiation therapy 64 Occlusive Disease 64 underwent resection 64 Fractional Flow Reserve 63 diagnostic angiography 63 IABP 63 Cardiotoxicity 63 Severe Asthma 63 Major Adverse Cardiac 63 prospectively stratified 63 beta blocker therapy 63 postoperative complication 63 Prospective Randomized Trial 63 death reinfarction 63 LVEF 63 Phase III Clinical Trial 63 carotid endarterectomy 63 Pelvic Organ Prolapse 63 Invasive Breast Cancer 63 rosuvastatin #mg 63 Brain Metastases 63 Atherosclerotic 63 fondaparinux 63 Dual Antiplatelet Therapy 63 Cilostazol 63 Antiplatelet Therapy 63 Bare Metal Stent 63 perioperative mortality 63 Atrial 63 INCB# [003] 63 Soft Tissue Sarcoma 63 Decompensated Heart Failure 63 oral anticoagulation 63 STEMI patients 63 fibrinolysis 63 BENICAR 63 superficial femoral 63 Prospective Multicenter 63 Placebo Controlled Trial 63 Placebo Controlled Study 63 secondary efficacy endpoint 63 Intervention Trial 63 hemostatic efficacy 63 CLARITY TIMI 63 percutaneous intervention 63 Percutaneous Transluminal Coronary Angioplasty 63 Randomized Controlled Trial 63 Systolic Blood Pressure 63 Diabetic Patients 63 intraobserver 63 Refractory Angina 63 coronary angiography 63 Tumor Response 63 TAXUS Express Stent 63 Radical Prostatectomy 63 serum phosphorous 63 angiographically 63 antithrombotic therapy 63 ARCOXIA 63 Follicular Lymphoma 63 functional mitral regurgitation 63 oral antidiabetic medication 63 Hemodialysis Patients 63 ST elevation myocardial 63 Vascugel ® 63 Cardiovascular Risk 63 Adjuvant Chemotherapy 63 Ventricular Arrhythmias 63 Embolic Protection Device 63 Intracoronary 63 colorectal liver metastases 63 ICD implantation 63 Lenalidomide 63 Adjunctive 63 multivessel disease 63 NSABP B 63 pulmonary artery banding 63 Clopidogrel 63 prospective randomized controlled 63 stenoses 63 revascularisation 63 Androgen Deprivation Therapy 63 myocardial viability 63 Cardiopulmonary bypass 63 PRoFESS 63 relapsed MM 63 Implantable Cardioverter Defibrillator 63 Ambulatory Blood Pressure 63 estimated glomerular filtration 63 Sentinel Lymph Node Biopsy 63 FOLFOX4 63 antiplatelet agents 63 underwent coronary angiography 63 prospective randomized multicenter 63 NIHSS 63 Renal Cell Carcinoma 63 eptifibatide 63 Pivotal Clinical Trial 63 drug eluting stent implantation 63 Insulin Therapy 63 CIMZIA TM certolizumab pegol 63 Cardiogenic Shock 63 complement inhibitor eculizumab 63 Venous Thrombosis 63 D dimer 63 GP IIb IIIa inhibitors 63 everolimus eluting stent 63 morphometric vertebral fractures 63 Combination Treatment 63 Asymptomatic 63 COPAXONE R 63 ventricular fibrillation VF 63 Ureteral 63 F FDG PET 63 upper endoscopy 63 Sustained Virologic Response 63 CIMZIA ™ 63 Controlled Trial 63 Tiotropium 63 Orthostatic Hypotension 63 Score TOS 63 thromboembolic complications 63 STENT 63 Newly Diagnosed Multiple Myeloma 63 gastroduodenal 63 Prolongs Survival 63 DAPT 63 Endovascular Treatment 63 Accelerated Partial Breast Irradiation 63 prostate TURP 63 Coronary CTA 63 Bare Metal Stents 63 heparin induced thrombocytopenia 63 fosbretabulin 63 Postoperative 63 Knee Osteoarthritis 63 contrast echocardiography 63 histologically confirmed 63 thromboses 63 Rheumatoid Arthritis Patients 63 Long Term Efficacy 63 eplerenone 62 concomitant medications 62 lung resection 62 Estrogen Receptor 62 radical cystectomy 62 artery occlusion 62 Coronary Artery Calcium 62 Pharmacokinetics PK 62 symptomatic intracranial 62 deep vein thromboses 62 prospective multicentre 62 SYNTAX trial 62 Total Hip Arthroplasty 62 Pulmonary Arterial Hypertension 62 NCT# ClinicalTrials.gov 62 Thrombotic 62 transurethral 62 pretest probability 62 melphalan prednisone 62 thromboembolism 62 definite stent thrombosis 62 parathyroidectomy 62 Chemoradiation 62 cerebrovascular events 62 Non Alcoholic Steatohepatitis 62 Renal Impairment 62 IIIa inhibitor 62 trials RCTs 62 Colorectal Cancer Patients 62 Sudden Cardiac Death 62 Renal Cell Carcinoma RCC 62 stable angina 62 Improves Survival 62 rebleeding 62 Coronary Revascularization 62 postprocedure 62 esophagogastric 62 Endovascular Valve Edge 62 Post Operative 62 transcranial Doppler 62 tibial shaft 62 INTEGRILIN R 62 Coronary Artery Bypass Grafting 62 patients undergoing CABG 62 Percutaneous Tibial Nerve Stimulation 62 acute ischemic stroke 62 binary restenosis 62 everolimus eluting stents 62 renal artery stenosis 62 cinacalcet 62 perioperatively 62 Crohn Disease Activity 62 multidetector computed tomography 62 recombinant tissue plasminogen 62 Hematological 62 Patients Receiving 62 vWD 62 TAXUS ATLAS 62 GORE TAG Device 62 dosage regimens 62 prospectively defined 62 tracheal intubation 62 multivariate Cox 62 Prognostic Value 62 IV NSCLC 62 ACE Inhibitors 62 Neovascular AMD 62 severe exacerbations 62 arterial thromboembolic events 62 non valvular atrial 62 lipid lowering drugs 62 VTE prophylaxis 62 Intracerebral Hemorrhage 62 Disease Progression 62 cTnI 62 calculated creatinine clearance 62 Solid Tumours 62 adenotonsillectomy 62 Digital Mammographic Imaging 62 nicardipine 62 neoadjuvant 62 Perforomist Inhalation Solution 62 zotarolimus eluting stent 62 Embolization 62 Antiplatelet 62 endarterectomy 62 Controlled Study 62 UA NSTEMI 62 prespecified secondary 62 Is Well Tolerated 62 Statistically Significant 62 aspirin clopidogrel 62 transthoracic echocardiography 62 intravenous thrombolysis 62 Vertebroplasty 62 occlusion CRVO 62 icatibant 62 myocardial ischemia 62 Prostatectomy 62 perioperative complications 62 GOUT 62 ischemia driven 62 Improves Outcomes 62 bivalirudin monotherapy 62 postoperative atrial fibrillation 62 Lung Cancer Trial 62 ritonavir boosted 62 randomized multicenter 62 Chronic HCV 62 Fibromyalgia Impact Questionnaire 62 placebo controlled Phase III 62 CK MB 62 acute STEMI 62 calcaneal fractures 62 Cryoablation 62 Well Tolerated 62 desvenlafaxine succinate 62 CTEPH 62 pelvic lymphadenectomy 62 Non Responders 62 LUMINATE 62 stage IIIb IV 62 multicenter randomized clinical 62 Clinical Efficacy 62 Angiogram 62 Diabetic Foot Ulcer 62 nonfatal MI 62 Meta Analysis 62 Hormone Refractory Prostate Cancer 62 Severity Index PASI 62 ULORIC 62 VADT 62 leiomyomas 62 ventricular dyssynchrony 62 Tolerability 62 valvular disease 62 Taxus Stent 62 ARB telmisartan 62 Free Survival PFS 62 intravenous tPA 62 multicentre 62 Advanced Renal Cell 62 multicenter Phase III 62 Chronic Sinusitis 62 bypass grafting 62 upper gastrointestinal bleeding 62 Study Evaluating 62 HGPIN 62 balloon dilation 62 asymptomatic carotid stenosis 62 venography 62 Postmenopausal Women 62 Randomized Controlled 62 metastatic malignant 62 EchoCRT 62 intracoronary 62 Total Knee Arthroplasty 62 FFR measurements 62 renal artery stenting 62 AA Amyloidosis 62 virological response 62 Cystectomy 62 XIENCE V demonstrated 62 haematologic 62 percutaneous vertebroplasty 62 angiotensin converting enzyme inhibitors 62 Subarachnoid hemorrhage 62 Severity MSCS score 62 Stent Implantation 62 Contrast Enhanced 62 venous thromboembolic disease 62 Depressive Symptoms 62 Adalimumab 62 subanalysis 62 Observational Study 62 cerebral vasospasm 62 Defibrillation 62 colesevelam HCl 62 Neoadjuvant Chemotherapy 62 Montgomery Asberg Depression 62 recanalization 62 juvenile idiopathic arthritis 62 left ventricular systolic 62 Doxil ® 62 MDCT angiography 62 Obese Patients 61 QTc prolongation 61 Acute MI 61 epoetin alpha 61 ischemic complications 61 WallFlex Biliary RX 61 Relapsed Multiple Myeloma 61 bivalirudin alone 61 acute coronary syndromes 61 biochemical relapse 61 extracranial 61 Non inferiority 61 ximelagatran 61 Main Outcome Measure 61 chemoradiotherapy 61 longitudinal cohort study 61 candesartan cilexetil 61 See CLINICAL PHARMACOLOGY 61 Histologic 61 candesartan 61 SCD HeFT 61 proximal DVT 61 TRA 2P 61 Response Evaluation Criteria 61 recurrent glioblastoma multiforme 61 Clinical Outcomes Utilizing Revascularization 61 thrombotic complications 61 Clinical Relevance 61 Glucosamine Chondroitin Arthritis 61 aortic insufficiency 61 Nonsurgical 61 carotid revascularization 61 LV dysfunction 61 BARI 2D 61 variceal bleeding 61 multicenter prospective 61 Pain Intensity 61 Benign Prostatic Hyperplasia BPH 61 TEVAR 61 repair TEVAR 61 EUS FNA 61 diameter stenosis 61 transesophageal echocardiography 61 Radiation Dose 61 LVSD 61 preoperatively 61 VAD implantation 61 lymphadenectomy 61 State Examination MMSE 61 tumor lysis syndrome 61 Meta analyzes 61 ertapenem 61 Ramipril 61 Dyspnea 61 Myelodysplastic Syndromes 61 Platelet Aggregation 61 multicenter randomized placebo controlled 61 Endovascular Repair 61 Bone Mineral Density 61 systolic hypertension 61 refractory ischemia 61 cirrhotic patients 61 Secondary efficacy endpoints 61 Hematologic 61 Nephrectomy 61 MEND CABG 61 recurrent VTE 61 Multicentre 61 antegrade 61 J Am Coll 61 sirolimus eluting 61 multicenter multinational 61 Multicenter Study 61 acute coronary syndrome 61 glomerular filtration 61 hepatectomy 61 Thromboembolism 61 Systolic Hypertension 61 HCV RESPOND 2 61 Peripheral Vascular Disease 61 Gastric Cancer 61 GP IIb IIIa inhibitor 61 zonisamide SR 61 subgroup analyzes 61 infarction STEMI 61 Hepatocellular Carcinoma 61 HYVET 61 Diabetic Macular Edema 61 Complicated Skin 61 Valsartan 61 CYPHER R Sirolimus eluting 61 Nymox NX 61 systemic embolism 61 Embolic Protection 61 keloid scarring 61 Carotid Artery Stenting 61 Ischemia 61 oral rivaroxaban 61 placebo controlled clinical 61 Mitral Regurgitation 61 Clinical Evaluation 61 CYPHER ® Sirolimus eluting 61 revascularization 61 descending thoracic 61 Dialysis Outcomes 61 Unified Parkinson Disease 61 stable angina pectoris 61 multicenter randomized 61 endoscopic resection 61 hemorrhagic complications 61 phase IIIb 61 prospectively randomized 61 Anticoagulants 61 coronary arteriography 61 quantitative coronary angiography 61 Relapsing Remitting Multiple Sclerosis 61 Drug Eluting 61 paracentesis 61 Metastatic Colorectal Cancer 61 Randomized Trials 61 Less Invasive 61 aldosterone antagonists 61 mitomycin C 61 Sustained Efficacy 61 ILLUSTRATE 61 Sentinel Lymph Node 61 ONTARGET 61 Enhanced External Counterpulsation 61 Outpatient Setting 61 Aggrenox ® 61 XIENCE V Everolimus Eluting 61 surgical revascularization 61 LEXIVA r 61 RAVEL 61 irbesartan 61 fluvastatin 61 Heart Transplant Recipients 61 Solid Tumors criteria 61 methotrexate monotherapy 61 hemodynamically significant 61 abacavir Ziagen 61 ASTEROID 61 Mortality Risk 61 Increased Mortality 61 somatostatin analog 61 balloon valvuloplasty 61 recurrent venous thromboembolism 61 FDG PET imaging 61 Scale EDSS 61 ACUITY trial 61 R# #mg BID 61 dabigatran etexilate 61 Intravesical 61 endoscopic ultrasonography 61 Pharmacodynamics 61 Randomized controlled 61 Hemolysis 61 Peginterferon Alfa 2a 61 certolizumab 61 immunohistochemical 61 Lower Limb 61 Rating Scale MADRS 61 atherothrombotic disease 61 subtrochanteric 61 ALA PDT 61 Nitinol Stent 61 Randomized Phase II 61 Coagulation 61 nonfatal myocardial infarction 61 abciximab 61 Atypical Hemolytic Uremic Syndrome 61 Blocked Arteries 61 Decitabine 61 Physical Function 61 TAXUS Liberte Long 61 Mycophenolate Mofetil 61 Arteriovenous 61 Postoperative complications 61 BRIM2 61 Stenting Trial 61 platelet inhibitor 61 PROMUS TM 61 Pediatric Patients 61 transrectal ultrasound guided 61 atherosclerotic renal artery stenosis 61 Thrombus 61 Systemic Lupus Erythematosus SLE 61 stent implantation 61 Occlusion 61 BYSTOLIC 61 hyperacute 61 Embolic 61 GAMMAGARD 61 noninferiority 61 Atacand ® 61 Lesion 61 Prognostic Significance 61 vasospasm 61 Heparin Bioactive Surface 61 Vertebral Compression Fractures 61 hemodynamic variables 61 univariate 61 Adjuvant Treatment 61 Adenomas 61 Feasibility Trial 61 cytoreductive surgery 61 Hepatocellular Carcinoma HCC 61 platelet reactivity 61 #Gy 61 Systemic Sclerosis 61 Optical Coherence Tomography 61 Montgomery Åsberg Depression 61 invasive candidiasis 61 prospective randomized placebo 61 CIMZIA TM 61 Neoadjuvant 61 Localized Prostate Cancer 61 HPA axis suppression 61 underwent CABG 61 MADIT 61 ACRIN 61 Robotic Assisted 61 adrenalectomy 61 ß blockers 61 Mitomycin C 61 Alzheimer Disease Assessment 61 SIMPADICO 61 obscure gastrointestinal bleeding 61 D Dimer 61 Breast Density 61 Contrast Agent 61 bolus dose 61 TRUS 61 liver transplant recipients 61 Telmisartan 61 arteriography 61 #mg BID [001] 61 Statin Therapy 61 elective PCI 61 Breast Cancer Recurrence 61 Nebulized 61 mycophenolate mofetil 61 gastric varices 61 mitral stenosis 61 histologically proven 61 intracerebral hemorrhage 61 TAVR 61 Acute Heart Failure 61 Acute Myocardial Infarction AMI 60 HCV Genotype 60 Ankylosing Spondylitis 60 Intraoperative 60 cardiopulmonary bypass CPB 60 TEAEs 60 adenoma recurrence 60 Randomized Double blind 60 Candesartan 60 paclitaxel eluting stents 60 percutaneous coronary intervention 60 PERSEUS 60 postoperative morbidity 60 prognostic variables 60 mcg BID 60 VAPRISOL 60 anticoagulation therapy 60 esophagectomy 60 VATS lobectomy 60 International Prostate Symptom 60 sirolimus eluting stent 60 CABG Surgery 60 metastatic neuroendocrine tumors 60 biliary tract cancer 60 radiotherapy RT 60 Secondary endpoints included 60 PICSO ® 60 Clinical Trial Results 60 ENDEAVOR II 60 DOXIL 60 STEMI 60 Diffuse Large B 60 creatinine clearance 60 clot busting therapy 60 MADRS score 60 nonischemic 60 PsA 60 ACE Inhibitor 60 non squamous NSCLC 60 #F FDG PET 60 radical nephrectomy 60 IIIb 60 ACC AHA 60 riociguat 60 Endoluminal 60 Lipid Lowering Treatment 60 Kidney Transplant Patients 60 Left Ventricular Ejection Fraction 60 clot dissolving drug 60 Visual Analogue Scale VAS 60 PRADAXA 60 Skin sterol 60 Liver Failure 60 coronary revascularisation 60 PAOD 60 decompressive surgery 60 mechanically ventilated patients 60 myocardial necrosis 60 VT VF 60 Biphasic 60 randomized blinded 60 intima media thickness 60 Pioglitazone 60 coronary CT angiography 60 Transesophageal 60 myocardial infarction MI 60 Intra operative 60 EINSTEIN DVT 60 nadolol 60 myocardial infarction stroke 60 Phase IIIb 60 multicentre randomized controlled 60 MULTAQ 60 Stable Angina 60 preoperative PSA 60 Randomized Double Blind 60 peripheral arterial occlusive disease 60 ribavirin RBV 60 Zoledronic Acid 60 Metabolic Efficiency 60 noninferior 60 extubation 60 Investigational Drug 60 carotid artery blockage 60 FFR guided treatment 60 Drug Eluting Stent 60 direct thrombin inhibitors 60 cerebral perfusion 60 Nilotinib 60 atrioventricular block 60 undetectable HBV DNA 60 computed tomographic 60 Artery Disease 60 Squamous Cell Carcinoma 60 revascularization procedure 60 #mg QD [002] 60 Reduces Mortality 60 Chronic Renal Failure 60 NSTEMI 60 severe neutropenia 60 Bronchial Thermoplasty 60 APTIVUS r 60 Predict Risk 60 landmark ATHENA trial 60 intracranial hemorrhage ICH 60 Cognitive Function 60 intravesical therapy 60 tamsulosin 60 Juvenile Idiopathic Arthritis 60 Non Alcoholic Fatty 60 graft dysfunction 60 Histological 60 VIIBRYD 60 endotracheal intubation 60 II Clinical Trial 60 Stent Graft 60 activated partial thromboplastin 60 paroxysmal atrial fibrillation 60 Platinol ® 60 cardiogenic shock 60 Arimidex Tamoxifen Alone 60 Immunosuppression 60 NYHA 60 Rivaroxaban 60 VerifyNow 60 C Reactive Protein 60 median sternotomy 60 antiplatelet agent 60 ORIF 60 dalteparin 60 clevidipine 60 undergoing coronary angiography 60 PD2i R 60 Investigational Treatment 60 Contraindications 60 Treatment Regimen 60 carotid artery stent 60 Vasogen Celacade 60 CYPHER ® Stent 60 infarction NSTEMI 60 Phase 2b Clinical Trial 60 assessing T DM1 60 Hormone Receptor Positive 60 Adjunctive Therapy 60 thrombolytics 60 NIS LL 60 myocardial revascularization 60 dimensional echocardiography 60 Hypercholesterolemia 60 coronary interventions 60 ENDEAVOR IV 60 Intubation 60 Intra arterial 60 antiarrhythmic drug 60 Renal dysfunction 60 plain radiographs 60 Pivotal Phase III 60 Community Acquired Pneumonia 60 laboratory abnormalities 60 Minimally Invasive Treatment 60 esophageal carcinoma 60 Adverse Event 60 TAXUS Liberté stent 60 restenotic lesions 60 ventricular tachycardia VT 60 Monitoring ABPM 60 Long Term Outcomes 60 extracorporeal circulation 60 transabdominal 60 Surgical Treatment 60 HCV SPRINT 60 PRADAXA #mg 60 Induction Chemotherapy 60 Mean Symptom Complex 60 transfemoral 60 left ventricular LV 60 Congestive Heart Failure 60 pneumonectomy 60 sinus tachycardia 60 Treated Patients 60 Virologic 60 cardiac perfusion 60 GORE VIABAHN Endoprosthesis

Back to home page